StreetInsider.com News Articles

Abeona Therapeutics (ABEO) PT Raised to $22 at Oppenheimer

Mon, 09 Mar 2026 14:46:17 -0400

Oppenheimer analyst Andreas Argyrides raised the price target on Abeona Therapeutics (NASDAQ: ABEO) to $22.00 (from $19.00) while maintaining a Outperform rating.

The analyst comments "On Monday, Abeona provided an update on launch progress for ZEVASKYN (press release) ahead of formal year-end results planned for the morning of March 17th. We discussed recent progress with management and feel confident in the traction being observed as early launch efforts continue. The update this morning included detail on the single patient dosed in 4Q and early progress in 1Q26 following the restart of manufacturing in late January (annual manufacturing maintenance). We revise our

Abeona Therapeutics (ABEO) PT Raised to $22 at Oppenheimer

Mon, 09 Mar 2026 14:46:17 -0400

Oppenheimer analyst Andreas Argyrides raised the price target on Abeona Therapeutics (NASDAQ: ABEO) to $22.00 (from $19.00) while maintaining a Outperform rating.

Form 8-K ABEONA THERAPEUTICS INC. For: Mar 09

Mon, 09 Mar 2026 07:31:00 -0400

si-local-file:///var/storage/secattach/20260309/26128912.html

Form 8-K ABEONA THERAPEUTICS INC. For: Mar 09

Mon, 09 Mar 2026 07:31:00 -0400

si-local-file:///var/storage/secattach/20260309/26128912.html

Abeona reports progress in ZEVASKYN gene therapy commercial launch

Mon, 09 Mar 2026 07:30:22 -0400

Abeona Therapeutics Inc. (NASDAQ: ABEO) reported progress in the commercial launch of its gene therapy ZEVASKYN, with multiple patients treated and additional biopsies scheduled for the current quarter.

The company began commercial launch activities in the fourth quarter of 2025 after optimizing a release assay. The first patient treatment was completed in December, followed by a scheduled facility shutdown. Manufacturing resumed in late January 2026, with multiple biopsies collected and at least one patient completing treatment since then.

ZEVASKYN received FDA approval as an autologous gene therapy for treating wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa, a rare

Abeona Therapeutics® Provides Business Update Highlighting Building Momentum in ZEVASKYN® Commercial Launch

Mon, 09 Mar 2026 07:30:00 -0400

CLEVELAND, March 09, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced an update on the building momentum in the Company’s launch of FDA-approved ZEVASKYN (prademagene zamikeracel), a first-of-its-kind, autologous gene therapy for treating wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB).

Following the optimization of a release assay in 2025, ZEVASKYN commercial launch activities commenced in the fourth quarter, with the first patient treatment completed in December prior to a mandatory scheduled facility shutdown. Since resuming manufacturing in late January 2026, multiple biopsies have been collected, a patient

Abeona Therapeutics® Provides Business Update Highlighting Building Momentum in ZEVASKYN® Commercial Launch

Mon, 09 Mar 2026 07:30:00 -0400

Abeona Therapeutics® Announces Date of Fourth Quarter / Full Year 2025 Financial Results and Participation in Upcoming 2026 Leerink Global Healthcare Conference

Tue, 03 Mar 2026 07:30:00 -0400

CLEVELAND, March 03, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it will host a conference call on Tuesday, March 17, 2026 at 8:30 a.m. ET to discuss its fourth quarter and full year 2025 financial results and corporate progress.

The conference call will be available via phone and webcast. To access the call, dial 888-506-0062 (U.S. toll-free) or 973-528-0011 (international) and Entry Code: 977217 five minutes prior to the start of the call. A live, listen-only webcast and archived replay of the call can be accessed on the Investors & Media

Abeona Therapeutics® Announces Date of Fourth Quarter / Full Year 2025 Financial Results and Participation in Upcoming 2026 Leerink Global Healthcare Conference

Tue, 03 Mar 2026 07:30:00 -0400

Form SCHEDULE 13G/A ABEONA THERAPEUTICS INC. Filed by: Adage Capital Management, L.P.

Thu, 12 Feb 2026 09:08:00 -0400

si-local-file:///var/storage/secattach/20260212/25988530.html

Form SCHEDULE 13G/A ABEONA THERAPEUTICS INC. Filed by: Adage Capital Management, L.P.

Thu, 12 Feb 2026 09:08:00 -0400

si-local-file:///var/storage/secattach/20260212/25988530.html

Form 144 ABEONA THERAPEUTICS INC. Filed by: Silverstein Christine Berni

Mon, 09 Feb 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260209/25967916.html

Form 144 ABEONA THERAPEUTICS INC. Filed by: Silverstein Christine Berni

Mon, 09 Feb 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260209/25967916.html

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 09 Feb 2026 10:04:00 -0400

CLEVELAND, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

On January 31, 2026, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to seven individuals hired by Abeona, which equity awards relate to, in the aggregate, up to 28,676 restricted shares of Abeona common stock. One-third of the shares subject to such restricted stock awards

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 09 Feb 2026 10:04:00 -0400

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 09 Feb 2026 10:04:00 -0400

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 09 Feb 2026 10:04:00 -0400

Form 4 ABEONA THERAPEUTICS INC. For: Feb 02 Filed by: Silverstein Christine Berni

Wed, 04 Feb 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260204/25947573.html

Form 4 ABEONA THERAPEUTICS INC. For: Feb 02 Filed by: Silverstein Christine Berni

Wed, 04 Feb 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260204/25947573.html

Form 4 ABEONA THERAPEUTICS INC. For: Feb 02 Filed by: Wuchterl Donald A.

Mon, 02 Feb 2026 18:59:00 -0400

si-local-file:///var/storage/secattach/20260202/25932427.html

Form 4 ABEONA THERAPEUTICS INC. For: Feb 02 Filed by: Wuchterl Donald A.

Mon, 02 Feb 2026 18:59:00 -0400

si-local-file:///var/storage/secattach/20260202/25932427.html

Form 4 ABEONA THERAPEUTICS INC. For: Feb 02 Filed by: Crombez Eric

Mon, 02 Feb 2026 18:55:00 -0400

si-local-file:///var/storage/secattach/20260202/25932420.html

Form 4 ABEONA THERAPEUTICS INC. For: Feb 02 Filed by: Crombez Eric

Mon, 02 Feb 2026 18:55:00 -0400

si-local-file:///var/storage/secattach/20260202/25932420.html

Form 144 ABEONA THERAPEUTICS INC. Filed by: Wuchterl Donald A.

Mon, 02 Feb 2026 16:59:00 -0400

si-local-file:///var/storage/secattach/20260202/25931805.html

Form 144 ABEONA THERAPEUTICS INC. Filed by: Wuchterl Donald A.

Mon, 02 Feb 2026 16:59:00 -0400

si-local-file:///var/storage/secattach/20260202/25931805.html